SK862004A3 - Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan - Google Patents

Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan Download PDF

Info

Publication number
SK862004A3
SK862004A3 SK86-2004A SK862004A SK862004A3 SK 862004 A3 SK862004 A3 SK 862004A3 SK 862004 A SK862004 A SK 862004A SK 862004 A3 SK862004 A3 SK 862004A3
Authority
SK
Slovakia
Prior art keywords
cetuximab
solution
liquid pharmaceutical
pharmaceutical composition
polyoxyethylene
Prior art date
Application number
SK86-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Hanns-Christian Mahler
Robert Muller
Ulrike Martini-Marr
Udo Haas
Christiane Bachmann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK862004A3 publication Critical patent/SK862004A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK86-2004A 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan SK862004A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (1)

Publication Number Publication Date
SK862004A3 true SK862004A3 (en) 2004-07-07

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
SK86-2004A SK862004A3 (en) 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan

Country Status (18)

Country Link
US (1) US20040170632A1 (xx)
EP (1) EP1406658A1 (xx)
JP (1) JP2004536129A (xx)
KR (1) KR20040018458A (xx)
CN (1) CN1231264C (xx)
AR (1) AR039358A1 (xx)
BR (1) BR0211060A (xx)
CA (1) CA2453342A1 (xx)
CZ (1) CZ2004189A3 (xx)
DE (1) DE10133394A1 (xx)
HU (1) HUP0401046A3 (xx)
MX (1) MXPA04000340A (xx)
PE (1) PE20030433A1 (xx)
PL (1) PL364599A1 (xx)
RU (1) RU2004102395A (xx)
SK (1) SK862004A3 (xx)
WO (1) WO2003007988A1 (xx)
ZA (1) ZA200401161B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2236154T1 (en) 2003-02-10 2018-08-31 Biogen Ma Inc. THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
CN1953768B (zh) * 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
AU2005244768B2 (en) * 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗egfr抗体の固形物
SI1859793T1 (sl) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
TW200800181A (en) 2006-02-09 2008-01-01 Sankyo Co Pharmaceutical composition for anticancer
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
EP2081553B1 (en) * 2006-10-06 2020-08-12 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN112566652A (zh) 2018-06-25 2021-03-26 Jcr制药股份有限公司 含有蛋白的水性液体制剂
MX2021002444A (es) * 2018-08-31 2021-04-28 Amplyx Pharmaceuticals Inc Compuestos y metodos para el tratamiento de infecciones fungicas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
CA2222231A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
CN100360184C (zh) * 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂

Also Published As

Publication number Publication date
JP2004536129A (ja) 2004-12-02
CA2453342A1 (en) 2003-01-30
EP1406658A1 (de) 2004-04-14
HUP0401046A2 (en) 2006-04-28
RU2004102395A (ru) 2005-05-27
PE20030433A1 (es) 2003-05-24
CZ2004189A3 (cs) 2004-05-12
KR20040018458A (ko) 2004-03-03
BR0211060A (pt) 2004-07-20
WO2003007988A1 (de) 2003-01-30
DE10133394A1 (de) 2003-01-30
MXPA04000340A (es) 2004-05-04
HUP0401046A3 (en) 2006-11-28
PL364599A1 (en) 2004-12-13
US20040170632A1 (en) 2004-09-02
CN1231264C (zh) 2005-12-14
AR039358A1 (es) 2005-02-16
ZA200401161B (en) 2004-10-22
CN1527724A (zh) 2004-09-08

Similar Documents

Publication Publication Date Title
AU2013255413B2 (en) Pharmaceutical formulations of TNF-alpha antibodies
JP4317010B2 (ja) IgG抗体の安定な凍結乾燥医薬製剤
TWI322693B (en) Pharmaceutical preparation comprising an antibody against the egf receptor
JP7473603B2 (ja) 液体医薬組成物
SK862004A3 (en) Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
CN103068367B (zh) 用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
JP2005513110A (ja) Egf受容体に対する抗体を含む凍結乾燥製剤
US11712472B2 (en) Pharmaceutical composition comprising anti-human TSLP receptor antibody
KR20080106636A (ko) 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액
CN114632150A (zh) 一种抗pd-l1人源化单克隆抗体的药物组合物
CN118076380A (zh) 免疫检查点抑制剂的药物配制物
JP3714951B2 (ja) Il−6含有薬剤組成物
JP6885875B2 (ja) 液体医薬組成物
CN112004522A (zh) 使用葡甲胺盐稳定包含蛋白的制剂的方法
BR112019012686A2 (pt) métodos e formulações para a redução do tempo de reconstituição de polipeptídeos liofilizados
TWI856084B (zh) 用於穩定含有蛋白質之配方之組合物及方法
WO2023233277A1 (en) Lyophilized pharmaceutical compositions of copper histidinate
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies

Legal Events

Date Code Title Description
FC9A Refused patent application